Phase I/II and phase II studies of targeted gene delivery In vivo: Intravenous rexin-g for chemotherapy-resistant sarcoma and osteosarcoma

Molecular Therapy

Volumn 17, Issue 9, 2009, Pages 1651-1657

  Chawla, Sant P ^a   Chua, Victoria S ^a   Fernandez, Lita ^a   Quon, Doris ^a   Saralou, Andreh ^a   Blackwelder, William C ^b,c   Hall, Frederick L ^d   Gordon, Erlinda M ^d  

^a Sarcoma Oncology Center   (United States)

^b Biologics Consulting Group   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d Epeius Biotechnologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; REXIN G; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INHIBITION; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA INTEGRATION; DNA REPLICATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENE TARGETING; HUMAN; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRESYNCOPE; PROGRESSION FREE SURVIVAL; SARCOMA; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; CYCLIN G; CYCLIN G1; CYCLINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; RETROVIRIDAE; SARCOMA; YOUNG ADULT;

EID: 69949145988     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.126     Document Type: Article

References (32)

1. Surveillance, Epidemiology, and End Results (SEER) Program (2007). Prevalence database: "US estimated 29-year LD counts on prevalence on 1/1/2004 by duration" for Bones and Joints Cancer. National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, based on the November 2006 SEER data submission. .
2. Longhi, A, Errani, C, De Paolis, M, Mercuri, M and Bacci, G (2006). Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 32: 423-436.
3. Kempf-Bielack, B, Bielack, SS, Jürgens, H, Branscheid, D, Berdel, WE, Exner, GU et al. (2005). Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559-568.
4. Surveillance, Epidemiology, and End Results (SEER) Program (2007). Prevalence database: "US estimated 29-year LD counts on prevalence on 1/1/2004 by duration" for Soft Tissue including Heart Cancer. National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, based on the November 2006 SEER data submission. .
5. Milano, A, Apice, G, Ferrari, E, Fazioli, F, de Rosa, V, de Luna, AS et al. (2006). New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol 59: 74-84.
6. Mocellin, S, Rossi, CR, Brandes, A and Nitti, D (2006). Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treat Rev 32: 9-27.
7. Geer, RJ, Woodruff, J, Casper, ES and Brennan, MF (1992). Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 127: 1285-1289.
8. Karakousis, CP and Zografos, GC (2002). Radiation therapy for high grade soft tissue sarcomas of the extremities treated with limb-preserving surgery. Eur J Surg Oncol 28: 431-436.
9. Pisters, PW, Leung, DH, Woodruff, J, Shi, W and Brennan, MF (1996). Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14: 1679-1689.
10. Cormier, JN and Pollock, RE (2004). Soft tissue sarcomas. CA Cancer J Clin 54: 94-109.
11. Demetri, GD (1998). Major developments in the understanding and treatment of soft-tissue sarcomas in adults. Curr Opin Oncol 10 343-347.
12. Meyers, PA, Schwartz, CL, Krailo, MD, Healey, JH, Bernstein, ML, Betcher, D et al. (2008). Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 26: 633-638.
13. Mori, K, Rédini, F, Gouin, F, Cherrier, B and Heymann, D (2006). Osteosarcoma: Current status of immunotherapy and future trends (Review). Oncol Rep 15: 693-700.
14. Witlox, MA, Lamfers, ML, Wuisman, PI, Curiel, DT and Siegal, GP (2007). Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone 40: 797-812.
15. Waehler, R, Russell, SJ and Curiel, DT (2007). Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587.
16. Kaplan, E and Meier, P (1958). Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481.
17. Skotzko, M, Wu, L, Anderson, WF, Gordon, EM and Hall, FL (1995). Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 55: 5493-5498.
18. Gordon, EM, Chen, ZH, Liu, L, Whitley, M, Liu, L, Wei, D et al. (2001). Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12: 193-204.
19. Oncologic "Threshold of Credibility" Paradigm being explored at FDA (2004): "The Pink Sheet" Prescription Pharmaceuticals and Biotechnology 66: P. 15.
20. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. DHHS, FDA, CDER, CBER, (2007): 1-19.
21. Storer, BE (1989). Design and analysis of phase I clinical trials. Biometrics 45: 925-937.
22. The NCI Common Terminology Criteria for Adverse Events Version 3 (2003). Cancer Therapy Evaluation Program DCTD, NCI, NIH, DHHS, (http://ctep.cancer.gov): 1-72.
23. Hall, FL, Liu, L, Zhu, NL, Stapfer, M, Anderson, WF, Beart, RW et al. (2000). Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 11: 983-993.
24. Xu, F, Prescott, MF, Liu, PX, Chen, ZH, Liau, G, Gordon, EM et al. (2001). Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med 8: 19-30.
25. Gordon, EM, Cornelio, GH, Lorenzo, CC, Levy, JP, Reed, RA, Liu, L et al. (2004). First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol 24: 177-185.
26. Gordon, EM, Lopez, FF, Cornelio, GH, Lorenzo, CC, Levy, JP, Reed, RA et al. (2006). Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: Three-year clinical experience. Int J Oncol 29: 1053-1064.
27. Guidance for Industry: Supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors (2006). UUSPHS, FDA, CBER: 1-13.
28. Galanis, E, Carlson, SK, Foster, NR, Lowe, V, Quevedo, F, McWilliams, RR et al. (2008). Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther 16: 979-984.
29. Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubinstein, L et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
30. Young, H, Baum, R, Cremerius, U, Herholz, K, Hoekstra, O, Lammertsma, AA et al. (1999). Measurement of clinical and subclinical tumour response using [18F]fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782.
31. Choi, H, Charnsangavej, C, Faria, SC, Macapinlac, HA, Burgess, MA, Patel, SR et al. (2007). Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25: 1752-1759.
32. Tabata, N, Miyazawa, M, Fujisawa, R, Takei, YA, Abe, H and Hashimoto, K (2000). Establishment of monoclonal anti-retroviral gp70 autoantibodies from MRL/lpr lupus mice and induction of glomerular gp70 deposition and pathology by transfer into non-autoimmune mice. J Virol 74: 4116-4126.